Aharon Gil 4

4 · DELCATH SYSTEMS, INC. · Filed Nov 1, 2024

Form 4

Period: 2024-10-30

Director

Transactions

Exercise/Conversion
Tranche B warrants to purchase F-4 Preferred Stock
2024-10-30$1000.00/sh+500$500,000→ 0 total(indirect: By Rosalind Advisors, Inc., the advisor to the Rosalind Funds)
Exercise: $1000.00From: 2023-03-29→ F-4 PREFERRED STOCK (500 underlying)
Expiration (Short)
8% CONVERTIBLE NOTE
2024-10-30+0→ 0 total(indirect: By Rosalind Advisors, Inc., the advisor to the Rosalind Funds)
Exercise: $0.00→ CASH

Footnotes (5)

[F1]Immediately exercisable
[F2]The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026. The Issuer announced on October 17, 2024 that it had recorded at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and therefore such Tranche B Warrants expire on November 7, 2024.
[F3]Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein
[F4]N/A
[F5]Delcath repaid the DELCATH SYSTEM - 8% CONVERTIBLE NOTE in full with cash of $1,423,333.

Documents

1 file